Form 4: Acelyrin Director Dawn Svoronos Reports Stock Option Grant

Director Dawn Svoronos reports the acquisition of stock options in Acelyrin, Inc.

Summary

• Dawn Svoronos, a director of Acelyrin, Inc. (SLRN), reported a transaction involving derivative securities.
• On June 7, 2024, Svoronos was granted a stock option to purchase 92,158 shares of Acelyrin's common stock at an exercise price of $4.46.
• The options vest on the earlier of June 7, 2025, or the day before the next annual meeting of stockholders following the grant date, contingent upon continued service as a director.
• Following the transaction, Svoronos beneficially owns 92,158 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns director interests with shareholder value.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term value creation.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised in the future.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates